BERYL DRUGS LIMITED
Regd. Off.: Ground Floor, 133, Kanchan Bagh, **Indore** - 452001 (M.P.)
Tel. : (0731) 2517677 | **E-mail :** beryldrugs25@yahoo.com | **CIN :** L02423MP1993PLC007840

Date: 30.05.2025

To,
The DCS-Listing
The Bombay Stock Exchange Limited,
Phiroze JeeJeebhoy Towers,
Dalal Street, Mumbai – 400 001

Sub: SUBMISSION OF AUDITED FINANCIAL RESULTS FOR THE YEAR ENDED 31ST MARCH, 2025 UNDER REGULATION 33 OF THE SECURITIES & EXCHANGE BOARD OF INDIA (LISTING OBLIGATION & DISCLOSURE REQUIREMENTS) REGULATION, 2015

Sir/ Madam,

Dear Sir(s), Pursuant to regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, in this connection, we are pleased to enclose the following:-

A. Statement of Audited Financial Results for the quarter and year ended 31st March, 2025, Statement of Assets and Liabilities and Cash Flow Statement.

B. Independent Auditor's Report on Audited Annual Financial Results for the quarter and year ended 31st March, 2025 by the Statutory Auditor M/s Subhash Chand Jain Anurag & Associates Chartered Accountants.

C. Declaration in respect of statement of impact of audit qualifications.

Kindly take on your record.

Thanking You,

Yours Faithfully,

For Beryl Drugs Limited

BERYL DRUGS LTD. Director

Sudhir Sethi
Chairman& Director
DIN: 00090172

Subhash Chand Jain Anurag & Associates
Chartered Accountants
104, Archana Apartment, 8-B, RatlamKothi, Indore – 452001 (M.P.)
Ph: 2519439, 2527682
Mob No: +91-93021-23882
Email: scjainca2004@yahoo.com

Independent Auditors' Report on the Quarterly and Year to date Audited IND AS Financial Results of Beryl Drugs Limited pursuant to the Regulation 33 and Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, as amended

To,
The Board of Directors,
Beryl Drugs Limited

Report on the audit of the IND AS Financial Results

Opinion

We have audited the accompanying statement of quarterly and year to date IND AS financial results of Beryl Drugs Limited (the "Company") for the quarter and year ended 31 March 2025, attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 and Regulation 52(4) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid annual financial results:

a. are presented in accordance with the requirements of Regulation 33 and Regulation 52(4) of the Listing Regulations.

b. give a true and fair view in conformity with the applicable accounting standards and other accounting principles generally accepted in India, of the net profit and other comprehensive income and other financial information of the Company for the quarter and year ended March 31, 2025.

SUBHASH CHAND JAIN ANURAG & ASSOCIATES
FRN. 004733C
INDORE
Chartered Accountants

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013, as amended ("the Act"). Our responsibilities under those Standards are further described in the "Auditor's Responsibilities for the Audit of the IND AS Financial Results" section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the Ind AS financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our opinion.

Emphasis of Matter

1. We draw attention to **Note 9** of the IND AS Financial Result for the Quarter and Year ended on 31st March 2025, which describes that, The Company has taken a loan from Kotak Mahindra Bank for Rs. 175 Lakhs on 01/11/2021, for which neither charge has been created nor satisfaction of charges made as on 31.03.2025, However the balance of said loan in current year Nil (P.Y. Rs. 143.51 Lakhs).

2. We draw attention to **Note 10** of the IND AS Financial Result for the Quarter and Year ended on 31st March 2025, which describes that, The Company has written back certain statutory liabilities on the grounds that it is not liable for their payment. The details of the liabilities written back as prior period item to statement of profit and loss account are as follows:

S. No.	Nature of the Statute	Nature of Dues	Amount (Rs. In Lacs)	Period to which the amount relates
1	MP Professional Tax Act, 1995	Professional Tax Payable	0.55	FY 1999-2000 to FY 2016-17
2	MP Professional Tax Act, 1995	Professional Tax Payable	0.29	FY 2023-24
3	MP Professional Tax Act, 1995	Professional Tax Payable	0.45	Old Year
4	Wealth Tax Act, 1957	Wealth Tax	3.91	Upto FY 2014-15
5	Finance Act, 1994	Service Tax	0.08	F.Y. 2016-17

3. We draw attention to **Note 11** of the IND AS Financial Result for the Quarter and Year ended on 31st March 2025, which describes that, The company has temporally discontinue production in FFS Section for upgradation as per revised Schedule M, WHO-GMP Norms w.e.f.



January 2025 and accordingly turnover of the company is lower from earlier year. Now, the company has got WHO-GMP certification on 27/03/2025.

4. We draw attention to **Note 12** of the IND AS Financial Result for the Quarter and Year ended on 31st March 2025, The company has written off trade receivable Rs. 23.75 Lakhs (PY Rs. 8.62 Lakhs) due to non-recoverability after continuous follow-up in during the year.

Our opinion is not modified in respect of this matter.

Management's Responsibilities for the IND AS Financial Results

The Statement has been prepared on the basis of the IND AS annual financial statements. The Board of Directors of the Company are responsible for the preparation and presentation of the Statement that gives a true and fair view of the net profit and other comprehensive income of the Company and other financial information in accordance with the applicable accounting standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 and 52 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the Statement, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so. The Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the IND AS Financial Results

Our objectives are to obtain reasonable assurance about whether the Statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an

SUBHASH CHAND JAIN ANURAG & ASSOCIATES
FRN. 004733C
INDORE
Chartered Accountants

auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the Statement.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to Ind AS financial statements in place and the operating effectiveness of such controls.

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.

- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

SUBHASH CHAND JAIN ANURAG & ASSOCIATES
FRN. C04733C
INDORE
Chartered Accountants

- Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represents the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matters

1. As described in Note No. 03 of the IND AS Financial Results The Statement includes the results for the Quarter ended 31 March 2025 being the balancing figure between audited figures in respect of the full financial year and the published year to date figures up to the third quarter of the current financial year which were subject to limited review by us.

2. The annual financial results dealt with by this report has been prepared for the express purpose of filing with the stock exchange. These results are based on and should be read with the audited financial statements of the company for the year ended March 31, 2025 on which we issued an unmodified opinion vide our report dated May 30, 2025.

Our opinion is not modified in respect of these matters.

For Subhash Chand Jain Anurag & Associates
Chartered Accountants
FRN-004733C



(Akshay Jain)
Partner
M. NO. 447487
UDIN: 25447487BMICQC2841

Date: 30/05/2025
Place: Indore

BERYL DRUGS LIMITED
Gr. Floor, 133, Kanchan Bagh, Indore (M.P.) – 452 001.
Tel./ Fax 0731-2517677
E-mail : beryldrugs25@yahoo.com
CIN : L02423MP1993PLC007840

ANNEXURE I

Part I — **Submission of Audited Financial Result by Companies Other than Banks**

(Rs in lakhs)

Statement of Audited Result for the Quarter/ year ended 31/03/2025

S.No.	Particulars	Quarter ended			Year Ended	
		3 months ended (31-03-2025)	Preceding 3 months ended (31-12-2024)	Corresponding 3 months ended in the previous year (31-03-2024)	Year to date figures for current period ended (31-03-2025)	Year to date figures for previous period ended (31-03-2024)
		Audited	Unaudited	Audited	Audited	Audited
1	**Revenue From Operations**					
	Net sales or Revenue from Operations	397.36	530.93	297.55	2114.62	2672.96
	Other operating revenues	124.60	9.34	23.28	140.86	39.51
	Total Revenue from operations (net)	**521.96**	**540.27**	**320.84**	**2255.48**	**2712.48**
2	**Expenses**					
(a)	Cost of materials consumed	246.48	262.77	288.39	1112.14	1331.36
(b)	Purchases of stock-in-trade	0.00	0.00	0.00	0.00	0.00
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	35.25	-79.41	14.24	-33.70	-16.72
(d)	Employee benefit expense	59.44	62.01	48.85	221.22	192.73
(e)	Finance costs	7.90	12.04	13.36	52.97	46.35
(f)	Depreciation and amortisation expense	31.65	31.26	31.54	124.56	120.07
(g)	Other Expenses	131.06	235.55	-33.26	691.72	937.71
	Total expenses	**511.78**	**524.22**	**363.13**	**2168.91**	**2611.51**
3	**Profit (loss) from operations before exceptional items and tax**	**10.18**	**16.05**	**-42.29**	**86.57**	**100.97**
4	Exceptional items	0.00	0.00	0.00	0.00	0.00
5	Profit (loss) before tax	**10.18**	**16.05**	**-42.29**	**86.57**	**100.97**
6	**Tax Expense**					
	Current tax	-14.58	8.51	-7.24	20.11	43.17
	Adjustments in respect of current income tax of prior years	0.00	-1.08	0.00	-1.09	0.72
	Deferred tax	9.58	3.40	-0.34	9.66	-19.79
	Total Tax Expenses	**-5.00**	**10.83**	**-7.57**	**28.68**	**24.11**
7	Net Profit (loss) for the period from continuing operations	15.19	5.22	-34.72	57.89	76.86
8	Net Profit (loss) from discontinuing operations before tax	0.00	0.00	0.00	0.00	0.00
9	Tax Expense of discontinuing operations	0.00	0.00	0.00	0.00	0.00
10	Net Profit (loss) from discontinuing operations after tax	0.00	0.00	0.00	0.00	0.00
11	**Net Profit (loss) for the Period**	**15.19**	**5.22**	**-34.72**	**57.89**	**76.86**
12	**Other comprehensive income**					
(i)	Items that will not be reclassified to Statement of Profit and Loss	-0.62	0.26	0.10	0.16	8.83
(ii)	Items that will be reclassified to Statement of Profit and Loss	0.00	0.00	0.00	0.00	0.00
13	**Total Comprehensive Income**	**14.57**	**5.48**	**-34.61**	**58.05**	**85.70**
14	**Details of equity share capital**					
	Paid-up equity share capital	507.17	507.17	507.17	507.17	507.17
	Face value of equity share capital	10.00	10.00	10.00	10.00	10.00
15	**Earnings per share**					
i	Basic earnings per share before extraordinary items	0.30	0.10	-0.68	1.14	1.52
ii	Diluted earnings per share before extraordinary items	0.30	0.10	-0.68	1.14	1.52

BERYL DRUGS LTD. Director

Notes to the Results:

1 The above Financial Results for the quarter and year ended 31st March 2025 have been reviewed by the Audit Committee and approved & taken on record by the Board at their Board meeting held on Friday 30th May 2025 and the financial result have been audited by the Statutory Auditors of the Company. The statutory Auditors have expressed an unmodified audit opinion on the results.

2 This Statement is as per the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.These audited financial results of the Company are prepared in accordance with the Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013(The Act) read with relevant Rules issued thereunder (Ind AS) and other accounting principles generally accepted in India and guidelines issued by the Securities and Exchange Borad of India (SEBI) .

3 The Statement includes the results for the Quarter ended 31 March 2025 being the balancing figure between audited figures in respect of the full financial year and the published year to date figures up to the third quarter of the current financial year which were subject to limited review.

4 Figures for the previous periods have been regrouped & recasted wherever necessary and minus figures are shown in brackets.

5 Depreciation on fixed assets is provided on written down value method as per the estimated remaining useful life of assets.

6 Revenue from Operations is net of GST & other deductions by customer.

7 Earnings per share amount is shown in Rupees.

8 The Company has identified "Pharmaceutical Industry" as the single operating segment for the continued operations in the standalone financial statements as per Ind AS 108 "Operating Segments" .

9 The Company has taken a loan from Kotak Mahindra Bank for Rs. 175 Lakhs on 01/11/2021, for which neither charge has been created nor satisfaction of charges made however as on 31.03.2025, The Company has current year Nil (P.Y. Rs. 143.51 Lakhs) o

10 The Company has written back certain statutory liabilities on the grounds that it is not liable for their payment. The details of the liabilities written back as prior period item to statement of profit and loss account are as follows:

S. No.	Nature of the Statute	Nature of Dues	Amount (Rs. In Lacs)	Period to which the amount relates
1	MP Professional Tax Act, 1995	Professional Tax Payable	0.55	FY 1999-2000 to FY 2016-17
2	MP Professional Tax Act, 1995	Professional Tax Payable	0.29	FY 2023-24
3	MP Professional Tax Act, 1995	Professional Tax Payable	0.45	Old Year
4	Wealth Tax Act, 1957	Wealth Tax	3.91	Upto FY 2014-15
5	Finance Act, 1994	Service Tax	0.08	F.Y. 2016-17

11 The company has temporally discontinue production in FFS Section for upgradation as per revised Schedule M, WHO-GMP Norms w.e.f. January 2025 and accordingly turnover of the company is lower from earlier year. Now, the company has got WHO-GMF

12 The company has written off trade receivable Rs. 23.75 Lakhs (PY Rs. 8.62 Lakhs) due to non-recoverability after continuous follow-up in during the year.

For and on behalf of the Board of Directors of
BERYL DRUGS LIMITED

Sanjay Sethi
Managing Director
DIN 00090277

Date: 30th May 2025
Place: Indore

Beryl Drugs Limited

CIN: L02423MP1993PLC007840

Registered Office: 133, Kanchan Bagh Indore (M.P.)-452001

Cash Flow Statement for the year ended 31st March 2025

S. No.	Particulars		For the year ended 31st March 2025		For the year ended 31st March 2024
A	**Cash Flow from Operating Activities**				
1	**Profit Before Tax**		**86.57**		**100.97**
	Add : Depreciation, Amortization and Impairment		124.56		120.07
	Add : Finance Cost		52.97		46.35
	Less : Rental Income		(13.37)		(12.73)
	Less : Dividened Income		0.00		(0.00)
	Less : Profit on Sale of Fixed Assets		0.00		(1.07)
	Less : Capital Gain on Sale of Shares		0.00		(0.00)
2	**Operating Profit Before Working Capital Changes**		**250.73**		**253.60**
3	**Adjustment for :**				
	(Increase) / Decrease in Operating Assets				
	Inventories	(64.26)		(20.55)	
	Trade Receivables	212.69		(68.38)	
	Other Financial Assets	39.10		45.57	
	Other Non Current Assets	(44.58)		0.33	
	Other Current Assets	(2.52)		14.39	
	Increase/(Decrease) in Operating Liabilities and Provisions		**140.43**		**(28.64)**
	Provisions	7.45		8.13	
	Trade Payables	(90.05)		-123.17	
	Other Financial Liabilities	(8.49)		-11.18	
	Other Current Liabilities	(18.41)		3.33	
			(109.50)		**(122.89)**
4	**Cash Flow used in Operations**		**281.67**		**102.06**
	Payment of Income Tax		(18.00)		(20.04)
	Net Cash Used in Operating Activities (A)		**263.67**		**82.02**
B	**Cash Flow from Investing Activities**				
1	Purchase of Property Plant and Equipments (PPE)		(218.51)		(135.16)
2	Proceeds from Government Grant in respect of tangible assets		90.44		0.00
3	Proceeds from Sale of tangible assets		0.00		2.10
4	Capital Advances and Others		75.00		(9.00)
5	Proceeds from Sale of Investments		0.00		21.90
6	Rental Income		13.37		12.73
7	Bank Balances other than Cash & Cash Equivalents		0.00		19.26
8	Payment of Liabilities Held for Sale		0.00		(20.00)
9	Dividend Income		0.00		0.00
	Net Cash Used in Investing Activities (B)		**(39.71)**		**(108.17)**
C	**Cash Flow from Financing Activities**				
1	Changes in Short Term Borrowings		(36.22)		79.69
2	Proceeds from Long Term Borrowings		124.84		0.0
3	Repayment of Long Term Borrowings		(190.66)		(24.51)
4	Finance Costs		(52.97)		(46.35)
5	Loans Given		0.00		0.00
6	Receipt of Loan		0.00		1.50
	Net Cash Used in Financing Activities (C)		**(155.01)**		**10.32**
	Net Increase/(Decrease) in Cash and Cash Equivalents (A+B+C)		68.95		(15.82)
	Cash and Cash Equivalents at the Beginning of the Year		**12.49**		**28.31**
	Cash and Cash Equivalents at the End of the Year		**81.44**		**12.49**
	Components of Cash and Cash Equivalents:				
	Cash on Hand		5.26		9.91
	Balance with bank in Current Account		1.18		2.59
	Fixed Deposit having maturity less than 3 months		75.00		0.00
			81.44		**12.49**

For and on behalf of the Board of Directors
Beryl Drugs Limited

Sanjay Seth
Managing Director
DIN : 00090277

BERYL DRUGS LTD. Director

Date : 30/05/2024
Place : Indore

Beryl Drugs Limited

CIN : L02423MP1993PLC007840

Registered Office : 133, Kanchan Bagh Colony, Indore (M.P.)-452001

Statement of assets and liabilities as at 31st March 2025

(Rs. In Lakhs)

S. No.	Particulars	As at 31st March 2025	As at 31st March 2024
I)	**Asset**		
A	**Non-Current Assets**		
1	Property, Plant and Equipment	600.46	596.14
2	Investment Property	19.59	20.38
3	Other Intangible assets	0.07	0.09
4	**Financial assets**		
	a) Investments	0.00	0.00
	b) Other Financial Assets	23.89	32.04
5	Deferred Tax Assets (Net)	0.61	10.33
6	Other Non-Current Assets	46.92	77.34
	Total Non Current Assets	**691.54**	**736.32**
B	**Current Assets**		
1	Inventories	190.28	126.02
2	**Financial Assets**		
	a) Investments		0
	b) Trade Receivable	545.71	758.39
	c) Cash and cash equivalents	81.44	12.49
	d) Bank balances other than (c) above	0.00	0.00
	c) Loans	0.00	0.00
	d) Other Financial Asstes	12.87	43.82
3	Current Tax Assets (Net)	0.00	0.00
4	Other current assets	74.16	71.64
	Total Current Assets	904.46	1012.37
C	**Assets held for Sale**	0.00	0.00
	Total Assets	**1596.00**	**1748.69**
II)	**Equity & Liabilities**		
A	**Equity**		
1	Equity Share Capital	509.37	509.37
2	Other Equity	441.01	382.96
	Total Equity	**950.38**	**892.33**
B	**Non-Current Liabilities**		
1	**Financial Liabilities**		
	a) Borrowings	173.58	240.38
	b) Other Financial Liabilities	0.00	0.00
2	Provisions	42.04	40.44
	Total Non-Current Liabilities	**215.62**	**280.82**
C	**Current Liabilities**		
1	**Financial Liabilities**		
	a) Borrowings	233.77	269.01
	b) Trade Payables		
	- total outstanding dues of micro enterprises and small enterprises	38.94	39.49
	- total outstanding dues of creditors other than micro enterprises and small enterprises	72.61	162.12
	c) Other Financial Liabilities	22.63	31.12
2	Other Current Liabilities	38.07	56.48
3	Provisions	11.97	6.34
4	Current Tax Liabilities (Net)	12.01	10.98
	Total Current Liabilities	**430.00**	**575.54**
D	**Liabilities held for Sale**		
	Total Liabilities and Equity	**1596.00**	**1748.69**

For, Beryl Drugs Limited

Sanjay Sethi
Director
DIN : 00090277

BERYL DRUGS LTD. Director

Date : 30/05/2025
Place : Indore

BERYL DRUGS LIMITED
Regd. Off.: Ground Floor, 133, Kanchan Bagh, **Indore** - 452001 (M.P.)
Tel. : (0731) 2517677 | **E-mail :** beryldrugs25@yahoo.com | **CIN :** L02423MP1993PLC007840

30th May, 2025

To,
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street,
MUMBAI – 400 001

Subject: Submission of declaration as per Second proviso to the Regulation 33(3)(d) of the SEBI (LODR) Regulation, 2015 for the Annual Audited Financial Results for the year ended 31st March, 2025.

Scrip Code: 524606

Dear Sirs,

We hereby submit the following declaration regarding unmodified Auditors Report on the Audited Financial Results/Statements for the year 31st March, 2025 as audited by the Auditors of the Company.

DECLARATION

Pursuant to the Regulation 33(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to **SEBI (Listing obligation and Disclosure Requirements) Regulations,2015, and amendments made therein vide SEBI Circular No SEBI/LAD-NRO/GN/2016-17 dated 25th May,2016 and further amendment dated 27th May, 2016 ,** We, the undersigned do hereby declare that in the Audit Report, accompanying the Annual Audited Financial Statements of **M/s Beryl Drugs Limited** for the financial year ended on 31.03.2025, the Auditor does not expressed any Modified Opinion(s)/ Audit Qualification(s)/ or other Reservation(s) and accordingly the the statement on impact of audit qualifications is not required to be given.

Kindly take the same on your record.

Thanking You,

Yours Faithfully,

For Beryl Drugs Limited **for Beryl Drugs Limited**

Sanjay Sethi **Ashish Baraskar**
Managing Director **Chief Financial Officer**
DIN: 00090277